Skip to main content
Premium Trial:

Request an Annual Quote

Gene-IT Licenses Sequence-Comparing Software to Pfizer

NEW YORK, Feb. 18 - Gene-IT over the weekend said that Pfizer has licensed its LASSAP gene sequence-comparing software.


Under terms of the deal, Pfizer scientists will be allowed to use the LASSAP technology for a number of tasks, including mining public and private mammalian genome databases.


Financial terms of the agreement were not disclosed.


Gene-IT, a privately held company based in France, launched LASSAP four years ago. The company has similar deals with Bayer Crop Science/Biogemma, Derwent, BioMerieux, DuPont, Servier Labs, and Organon.


In October 2001, Gene-IT opened a subsidiary in Los Altos, Calif., to help it carve a bigger foothold in the US market.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.